Who are ATB-346 low dose's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Celebrex, Cytotec, Codeine + Diclofenac, Diclofenac oral + Placebo Oral, Diclofenac sodium gel 3%, Escitalopram + Celecoxib.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/atb-346-low-dose.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

ATB-346 low dose — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ATB-346 low dose (ATB-346 low dose) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NSAID. Area: Pain.

phase 2 NSAID COX-2 Pain Small molecule Live · refreshed every 30 min

Target snapshot

ATB-346 low dose (ATB-346 low dose) — Antibe Therapeutics Inc.. ATB-346 low dose is a nonsteroidal anti-inflammatory drug (NSAID) that selectively targets COX-2 to reduce gastrointestinal toxicity.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ATB-346 low dose TARGET	ATB-346 low dose	Antibe Therapeutics Inc.	phase 2	NSAID	COX-2
Celebrex	celecoxib	Pfizer Inc. (originally Searle/Pharmacia)	marketed	Nonsteroidal Anti-inflammatory Drug [EPC]	COX-2	1998-12-31
Cytotec	Misoprostol	Pfizer	marketed	NSAID combined with prostaglandin analog	Cyclooxygenase (COX-1 and COX-2); Prostaglandin receptors	1988-01-01
Codeine + Diclofenac	Codeine + Diclofenac	University of Sao Paulo	marketed	Opioid + NSAID combination analgesic	Mu opioid receptor (codeine); COX-1 and COX-2 (diclofenac)
Diclofenac oral + Placebo Oral	Diclofenac oral + Placebo Oral	Hospital de Clinicas de Porto Alegre	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	COX-1 and COX-2
Diclofenac sodium gel 3%	Diclofenac sodium gel 3%	LEO Pharma	marketed	NSAID (nonsteroidal anti-inflammatory drug)	COX-1 and COX-2 (cyclooxygenase enzymes)
Escitalopram + Celecoxib	Escitalopram + Celecoxib	University of Pennsylvania	marketed	SSRI + selective COX-2 inhibitor combination	Serotonin transporter (SERT) and cyclooxygenase-2 (COX-2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2036-05-27 — Celebrex · 10722456 · Formulation · US
2036-05-27 — Celebrex · 10799517 · Formulation · US
2036-05-27 — Celebrex · 9949990 · Formulation · US
2036-05-27 — Celebrex · 9795620 · Formulation · US
2036-05-27 — Celebrex · 9572819 · Formulation · US
2036-05-27 — Celebrex · 10376527 · Formulation · US

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ATB-346 low dose — Competitive Intelligence Brief. https://druglandscape.com/ci/atb-346-low-dose. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing